Hubbard-Hall Acquires BioConversion Technology

Photo Credit: Hubbard-Hall

Hubbard-Hall acquired the assets of BioConversion Technology (BCT), a supplier of biologics and related chemistries for wastewater treatment. Jeremy Morgan, previously a vice president of technology at BCT, has joined Hubbard-Hall as product manager for biologics within the company’s AquaPure product line of wastewater specialties. Morgan is a graduate of Georgia Institute of Technology with a degree in chemical engineering and is a frequent speaker at water technology conferences. He reports to Robin Deal, AquaPure product manager.

BCT products are custom blends of specially selected bacterial strains for the metal finishing, food, pulp and paper, and petrochemical markets. The bacteria work under aerobic and anerobic conditions with no caustics or acids so as to not cause harm to pipes or wastewater equipment. BCT, formerly headquartered in Georgia, was founded in 2000 by Kathleen Renzi.

“The BCT line of products, combined with Jeremy’s expertise in biologics, round out our offerings to our industrial customer base,” says Hubbard-Hall CEO Molly Kellogg. “Bioaugmentation in metal finishing wastewater treatment is becoming more common as limits continue to tighten around Phosphorus, FOG and BOD. We now have a broader line to help our customers and, as always, the best technical team in the business.”